

**List of Drugs for Rare Cancers in Hong Kong**  
**香港罕見癌症藥物清單**

**Definition of Rare Cancers 罕見癌症定義**

Incidence rate of less than 6 per 100,000 persons per year 每年每 10 萬人中發病率低於 6 例 (source 資料來源: Rare Cancers Europe)

Incidence rate of less than 15 per 100,000 persons per year 每年每 10 萬人中發病率低於 15 例 (source 資料來源: National Cancer Institute - USA)

**Date Published 發佈日期: 2024.02** (Updates are shown in green 綠色字體為更新部分)

The information in this file is for reference only and not exhaustive. It is not intended to be a substitute for professional medical advice. Updated information will be published from time to time.

本文件資訊只供參考，並非詳盡無遺，亦不能取代醫生或其他合格醫療專業人員的建議。如有資料更新，將會不時發佈。

The content of the list is copyrighted by Rare Diseases Hong Kong (RDHK) and may not be reproduced, copied, downloaded or disseminated, in any way, for any commercial purpose, without prior written authorization and approval from RDHK. Individuals may print one hard copy for personal use, provided that content is unmodified and includes RDHK's copyright.

本清單內容為香港罕見病 (RDHK) 版權所有，事先未經RDHK書面授權和批准，不得以任何方式複製、複製、下載或傳播用於任何商業用途。個人使用可供複製或列印，惟內容未能修改且包含RDHK版權的部分。

The content of the list is copyrighted by Rare Diseases Hong Kong (RDHK) and may not be reproduced, copied, downloaded or disseminated, in any way, for any commercial purpose, without prior written authorization and approval from RDHK. Individuals may print one hard copy for personal use, provided that content is unmodified and includes RDHK's copyright.

No. 序	Ingredients 成分	Reference Indications 參考適應症	Cancer Types 癌症分類	Drug Formulary Category* 藥物名冊分類 *	Source of drug information 藥物資料來源
1	ABIRATERONE	For metastatic castration resistant prostate cancer (mCRPC) progressed on or after docetaxel-based chemotherapy regimen 適用於治療藥物或手術去勢抗性的轉移性前列腺癌，並且已使用過多西紫杉醇(Docetaxel)而治療無效者	Prostate cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
		For the treatment of adult men with metastatic castration resistant prostate cancer (mCRPC) who are unsuitable for Docetaxel treatment on the basis of predicted intolerance to Docetaxel 適用於治療成年男性藥物或手術去勢抗性的轉移性前列腺癌，而基於預期對多西紫杉醇(Docetaxel) 治療不耐受，患者不適合接受多西紫杉醇	Prostate cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
2	ACALABRUTINIB	Relapsed / refractory Chronic lymphocytic leukaemia (CLL) 復發或難治慢性淋巴細胞白血病	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
		Previously untreated chronic lymphocytic leukaemia (CLL) with unmutated IGHV 慢性淋巴細胞白血病，而患者未曾接受任何治療及沒有 IGHV 突變	Lymphatic system cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
		For adult patients with relapsed or refractory mantle cell lymphoma 用於治療患有復發或難治被套細胞淋巴瘤的成人患者	Blood and bone marrow cancer	Self-financed item Without Safety Net	MIMS HK
3	ACTINOMYCIN D	Ewing's sarcoma	Bone or soft tissue cancer	General Drugs	MIMS HK
		Wilm's tumour	Kidney cancer	General Drugs	MIMS HK
4	ALECTINIB	ALK+ve non-small cell lung cancer (NSCLC) (first-line treatment) 間變性淋巴瘤激酶(ALK)呈陽性非小細胞肺癌 (一線治療)	Lung cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
		ALK+ve metastatic non-small cell lung cancer (NSCLC), progressed on Crizotinib and intolerant to Ceritinib, or have CNS-progression after Crizotinib			
5	ALEMTUZUMAB	B cell chronic lymphocytic leukaemia	Blood and bone marrow cancer	Spceial Drugs	MIMS HK
6	APALUTAMIDE	Prostate cancer 前列腺癌	Prostate cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
7	ARSENIC TRIOXIDE	Acute promyelocytic leukaemia	Blood and bone marrow cancer	Spceial Drugs	MIMS HK
8	ASPARAGINASE	Acute lymphoblastic leukaemia	Blood and bone marrow cancer	General Drugs	MIMS HK
9	ATEZOLIZUMAB	For the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy. 適用於治療未曾接受全身系統性療程且晚期或無法切除的肝細胞癌(HCC)成年患者	Liver cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
10	ATEZOLIZUMAB	For EGFR-ve and ALK-ve metastatic non-small cell lung cancer (NSCLC) progressed on or following platinum-based chemotherapy 用於患有 EGFR 基因變異陰性及 ALK-陰性轉移性非小細胞肺癌(NSCLC) 並曾接受含鉑化療而病情惡化的患者	Lung cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
		As monotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a PD-L1 expression $\geq$ 50% tumour cells (TC) and who do not have EGFR mutant or ALK-positive NSCLC 作為單一藥物治療，用於沒有 EGFR 基因變異或 ALK 呈陽性的轉移性非小細胞肺癌 (NSCLC) 的成年患者之第一線治療，其腫瘤的 PD-L1 基因表達程度 $\geq$ 50%			
11	AVELUMAB	Monotherapy for the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are progression-free following platinum-based chemotherapy 用於鉑類化療後沒有惡化的局部晚期或轉移性泌尿道上皮細胞癌的成人患者的一線單一維持治療	Bladder cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website

12	Axitinib	Advanced renal cell carcinoma (RCC)	Blood and bone marrow cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
13	AZACITIDINE	Acute myeloid leukaemia (AML) 急性骨髓性白血病  Chronic myelomonocytic leukaemia (CMML) 慢性粒單細胞白血病  Myelodysplastic syndromes (MDS) 骨髓增生異常綜合症	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
14	BENDAMUSTINE	Chronic lymphocytic leukaemia, Multiple myeloma, Non-Hodgkin's Lymphoma	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	MIMS HK
15	BEVACIZUMAB	Glioblastoma	Brain cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	
		Cervical cancer	Cervical cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	
		First line treatment of RAS mutant metastatic colorectal cancer in combination with chemotherapy in adult patients indicated for intensive treatment OR First line treatment of RAS wild type metastatic colorectal cancer in combination with chemotherapy in adult patients indicated for intensive treatment who are unsuitable for or intolerant to Cetuximab / Panitumumab 作為第一線治療，配合化療用於需接受強化治療的RAS突變型之轉移性大腸直腸癌成人患者 或 作為第一線治療，配合化療用於需接受強化治療的RAS野生型之轉移性大腸直腸癌成人患者，而患者不適合接受西妥昔單抗/帕木單抗治療或產生不耐受 With carboplatin and paclitaxel for front-line fallopian tube [fallopian tube cancers] / primary peritoneal cancer 與卡鉑和紫杉醇併用於晚期輸卵管癌和原發性腹膜癌的第一線治療	Colorectal cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	
		Epithelial ovarian / fallopian tube / primary peritoneal cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website	
16	BLEOMYCIN	Testicular tumours	Germ cell tumor	General Drugs	MIMS HK
17	BLINATUMOMAB	Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukaemia	Blood and bone marrow cancer	Special Drugs	MIMS HK
18	BORTEZOMIB	Multiple myeloma	Bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	MIMS HK
		Mantle cell Lymphoma	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
19	BRENTUXIMAB VEDOTIN	For the treatment of adult patients with relapsed or refractory CD30+ Hodgkin Lymphoma (RR/HL): (i) following autologous stem cell transplant (ASCT), or (ii) following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option 用於成人患者，治療復發或難治性CD30+型何傑金氏淋巴瘤(HL)，而患者： (i) 已接受自身幹細胞移植，或 (ii) 經歷最少兩類自身幹細胞移植或多項化療的療程均屬不合適的選項  For the treatment of adult patients with relapsed or refractory systemic anaplastic large cell Lymphoma 用於成人患者，治療復發或難治性全身間變性大型細胞淋巴瘤  For the treatment of adult patients with CD30+ cutaneous T-cell Lymphoma (CTCL) after at least 1 prior systemic therapy	Bone marrow cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
20	BRENTUXIMAB VEDOTIN	Hodgkin's disease, Anaplastic large cell Lymphoma, CD-30 positive cutaneous T-cell Lymphoma	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
21	BRIGATINIB	ALK+ve non-small cell lung cancer (NSCLC) (first-line treatment) ALK呈陽性非小細胞肺癌  ALK+ve metastatic non-small cell lung cancer (NSCLC), progressed on Crizotinib and intolerant to Ceritinib, or have CNS-progression after Crizotinib	Lung cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
22	BUSULPHAN	Chronic myeloid leukemia (CML)	Blood and bone marrow cancer	Special Drugs	MIMS HK
23	CABOZANTINIB (CABOMETYX)	Monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated w/ sorafenib.	Liver cancer	Self-financed item Without Safety Net	MIMS HK
24	CARBOPLATIN	Small cell lung cancer	Lung cancer	General Drugs	MIMS HK
25	CARFILZOMIB	Multiple myeloma	Bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	MIMS HK
26	CARMUSTINE	Malignant glioma	Brain and spinal cord cancer	General Drugs	MIMS HK
		Recurrent glioblastoma multiforme	Brain cancer	General Drugs	MIMS HK
		Hodgkin's disease, Non-Hodgkin's Lymphoma	Lymphatic system cancer	General Drugs	MIMS HK

27	CERITINIB	ALK+ve non-small cell lung cancer (NSCLC) (first line treatment) ALK 呈陽性非小細胞肺癌  ALK+ve advanced non-small cell lung cancer (NSCLC) previously treated with Crizotinib 曾經接受吉奧替尼療程，ALK 呈陽性晚期非小細胞肺癌的成年患者	Lung cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
28	CETUXIMAB	Locally advanced squamous cell carcinoma of the head and neck	Head and neck cancer	Spceial Drugs	MIMS HK
		Metastatic squamous cell carcinoma of the head and neck	Head and neck cancer	Self-financed item Without Safety Net	MIMS HK
		Recurrent squamous cell carcinoma of the head and neck			
		RAS wild-type colorectal cancer	Colorectal cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
29	CHLORAMBUCIL	Chronic lymphocytic leukaemia	Blood and bone marrow cancer	General Drugs	MIMS HK
		Hodgkin's disease, Non-Hodgkin's Lymphoma	Lymphatic system cancer	General Drugs	MIMS HK
30	CISPLATIN	Metastatic testicular tumours	Germ cell tumor	General Drugs	MIMS HK
31	CLADRIBINE	B cell chronic lymphocytic leukaemia	Blood and bone marrow cancer	General Drugs	MIMS HK
		Hairy cell leukaemia			
32	CLADRIBINE (MAVENCLAD)	Waldenstrom's macroglobulinaemia	Lymphatic system cancer	Spceial Drugs	MIMS HK
		B cell chronic lymphocytic leukaemia	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	MIMS HK
		Hairy cell leukaemia			
		Waldenstrom's macroglobulinaemia	Lymphatic system cancer	Self-financed item With Safety Net (Samaritan Fund)	MIMS HK
33	CLOFARABINE	Acute lymphoblastic leukaemia	Blood and bone marrow cancer	Spceial Drugs	MIMS HK
34	CRISANTASPASE (ASPARAGINASE ERW)	Acute lymphoblastic leukaemia	Blood and bone marrow cancer	Spceial Drugs	MIMS HK
35	CRIZOTINIB	ALK+ve non-small cell lung cancer (NSCLC) ALK 呈陽性非小細胞肺癌	Lung cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
		ROS1-positive non-small cell lung cancer (NSCLC) ROS1 呈陽性非小細胞肺癌			
36	CYCLOPHOSPHAMIDE	Acute lymphocytic leukaemia, Acute myeloid leukaemia, Chronic lymphocytic leukaemia, Chronic myeloid leukaemia	Blood and bone marrow cancer	General Drugs	MIMS HK
		Advanced mycosis fungoides	Blood cancer	General Drugs	MIMS HK
		Multiple myeloma	Bone marrow cancer	General Drugs	MIMS HK
		Ewing's sarcoma	Bone or soft tissue cancer	General Drugs	MIMS HK
		Retinoblastoma	Eye cancer	General Drugs	MIMS HK
		Small cell lung cancer	Lung cancer	General Drugs	MIMS HK
		Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma	Lymphatic system cancer	General Drugs	MIMS HK
37	CYTARABINE	Leukaemic meningitis	Blood and bone marrow cancer	General Drugs	MIMS HK
38	DABRAFENIB	For the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma 用於成年患者以治療BRAF V600突變呈陽性而不能切除的或轉移性黑色素瘤	Skin cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
		For the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection 作為術後輔助治療，用於已完全切除腫瘤的 BRAF V600突變 III 期黑色素瘤成人患者			
39	DACARBAZINE	Soft tissue sarcoma	Bone or soft tissue cancer	General Drugs	MIMS HK
		Hodgkin's disease	Lymphatic system cancer	General Drugs	MIMS HK
		Metastatic melanoma	Skin cancer	General Drugs	MIMS HK
40	DARATUMUMAB	Multiple myeloma	Bone marrow cancer	Self-financed item Without Safety Net	MIMS HK
41	DARATUMUMAB AND BORTEZOMIB	Systemic AL amyloidosis 全身性輕鏈類澱粉沉積症	Bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
		In combination with thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma (MM) who are eligible for autologous stem cell transplant 與沙利度胺和地塞米松併用，治療符合自體幹細胞移植條件的新診斷多發性骨髓瘤成年患者	Bone marrow cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
42	DASATINIB	Imatinib-resistant chronic myeloid leukaemia (CML) 對伊馬替尼(Imatinib)具抗藥性的慢性骨髓性白血病	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
		Imatinib-resistant philadelphia or BCR/ABL positive acute lymphoblastic leukaemia (ALL) 對伊馬替尼(Imatinib)具抗藥性及伴有費城染色體的急性淋巴細胞白血病			
		Newly diagnosed chronic myeloid leukaemia (CML) in chronic phase 處於慢性期及新斷症的慢性骨髓性白血病			
		Nilotinib-resistant chronic myeloid leukaemia (CML) 對尼洛替尼(Nilotinib)具抗藥性的慢性骨髓性白血病			

		Chronic myeloid leukaemia	Blood and bone marrow cancer	Special Drugs	MIMS HK
43	DAUNORUBICIN	Acute leukaemia	Blood and bone marrow cancer	General Drugs	MIMS HK
		AIDS-related Kaposi's sarcoma	Endothelial cell cancer	General Drugs	MIMS HK
44	DOCETAXEL	Head and neck cancer	Head and neck cancer	Special Drugs	MIMS HK
		Head and neck cancer	Head and neck cancer	Self-financed item Without Safety Net	MIMS HK
45	DOSTARLIMAB	Mismatch repair deficient/microsatellite instability-high recurrent or advanced endometrial cancer 伴隨錯配修復缺陷(dMMR)/高度微衛星不穩定性(MSI-H)的原發性晚期或復發性子宮內膜癌症	Endometrial cancer	Self-financed item Without Safety Net	HA Website
46	DOXORUBICIN	Acute leukaemia	Blood and bone marrow cancer	General Drugs	MIMS HK
		Osteosarcoma	Bone cancer	General Drugs	MIMS HK
		Advanced Soft tissue sarcoma	Bone or soft tissue cancer	General Drugs	MIMS HK
		Wilm's tumour	Kidney cancer	General Drugs	MIMS HK
		Hodgkin's Lymphoma	Lymphatic system cancer	General Drugs	MIMS HK
47	DOXORUBICIN (LIPOSOMAL)	Acute leukaemia	Blood and bone marrow cancer	Self-financed item Without Safety Net	MIMS HK
		Osteosarcoma	Bone cancer	Self-financed item Without Safety Net	MIMS HK
		Multiple myeloma	Bone marrow cancer	Self-financed item Without Safety Net	MIMS HK
		Advanced Soft tissue sarcoma	Bone or soft tissue cancer	Self-financed item Without Safety Net	MIMS HK
		AIDS-related Kaposi's sarcoma	Endothelial cell cancer	Self-financed item Without Safety Net	MIMS HK
		Wilm's tumour	Kidney cancer	Self-financed item Without Safety Net	MIMS HK
		Hodgkin's Lymphoma	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
		Non-Hodgkin's Lymphoma	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
		Second-line of platinum refractory or subsequent treatment of platinum resistant advanced ovarian cancer 鉑化合物無效後的第二線或後續鉑化合物抗藥的卵巢癌治療	Ovarian cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	MIMS HK
48	DURVALUMAB	Unresectable and stage III non-small cell lung cancer (NSCLC) not progressed following concurrent platinum-based chemotherapy and radiation therapy	Lung cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
49	ENZALUTAMIDE	For metastatic castration resistant prostate cancer (mCRPC) progressed on or after docetaxel-based chemotherapy regimen 適用於治療藥物或手術去勢抗性的轉移性前列腺癌，並且已使用過多西紫杉醇(Docetaxel)而治療無效者  For the treatment of adult men with metastatic castration resistant prostate cancer (mCRPC) who are unsuitable for Docetaxel treatment on the basis of predicted intolerance to Docetaxel 適用於治療成年男性藥物或手術去勢抗性的轉移性前列腺癌，而其於預期對多西紫杉醇(Docetaxel)治療不耐受，患者不適合接受多西紫杉醇 Metastatic Hormone-Sensitive Prostate Cancer	Prostate cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
			Prostate cancer	Self-financed item Without Safety Net	HA Website
50	EPIRUBICIN	Acute leukaemia	Blood and bone marrow cancer	General Drugs	MIMS HK
		Multiple myeloma	Bone marrow cancer	General Drugs	MIMS HK
51	ERLOTINIB	Metastatic pancreatic cancer	Pancreatic cancer	Special Drugs	MIMS HK
52	ETOPOSIDE	Testicular cancer	Germ cell tumor	General Drugs	MIMS HK
		Small cell lung cancer	Lung cancer	General Drugs	MIMS HK
53	EVEROLIMUS (AFINITOR)	For HR+ve HER2-ve advanced breast cancer, in combination with Exemestane, in postmenopausal women with bone-only disease after recurrence or progression following a non-steroidal aromatase inhibitor. 與依西美坦 ( Exemestane ) 併用，治療停經後的晚期荷爾蒙接受體陽性、HER2 受體陰性骨轉移乳癌。患者先前已使用過非類固醇類之芳香環酶抑制劑治療無效	Breast cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	MIMS HK
54	EVEROLIMUS (AFINITOR) (OR EQUIV)	Unresectable or metastatic, well- or moderately-differentiated neuroendocrine tumours of pancreatic origin in adults w/ progressive disease	Pancreatic cancer	Self-financed item Without Safety Net	MIMS HK
		Neuroendocrine tumours of gastrointestinal origin	Gastrointestinal cancer	Special Drugs	MIMS HK
		Neuroendocrine tumours of lung origin	Lung cancer	Special Drugs	MIMS HK
		Neuroendocrine tumours of pancreatic origin	Pancreatic cancer	Special Drugs	MIMS HK
55	FLUDARABINE	B cell chronic lymphocytic leukaemia	Blood and bone marrow cancer	Special Drugs	MIMS HK
56	FLUOROURACIL	Pancreatic carcinoma	Pancreatic cancer	General Drugs	MIMS HK
		Superficial basal cell carcinoma			
57	GEMCITABINE	Cancer, pancreatic	Pancreatic cancer	General Drugs	MIMS HK

58	GEMTUZUMAB OZOGAMICIN	In combination with daunorubicin and cytarabine for the treatment of patients age 15 years and above with previously untreated, de novo CD33-positive acute myeloid leukaemia (AML), except acute promyelocytic leukaemia (APL) 與柔紅霉素及阿糖胞苷結合作用治療 15 歲及以上患有原發性 CD33 型呈陽性的急性骨髓性白血病(急性早幼骨髓性白血病除外)· 而之前未曾接受治療的患者	Blood and bone marrow cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
59	GILTERITINIB	Relapsed or refractory acute myeloid leukaemia (AML) 復發性或難治性急性骨髓性白血病	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
60	HYDROXYUREA	chronic myelogenous leukemia	Blood and bone marrow cancer	General Drugs	MIMS HK
61	IBRUTINIB	Relapsed or refractory mantle cell Lymphoma (MCL) 復發或難治性套細胞淋巴瘤  Chronic lymphocytic leukaemia (CLL) 慢性淋巴細胞白血病 As a single agent or in combination with rituximab for the treatment of adult patients with Waldenström's macroglobulinaemia (WM) with MYD88 gene mutation who have received at least one prior therapy 單獨使用或與利妥昔單抗併用, 治療曾接受至少一種治療並帶有 MYD88 基因突變的華氏巨球蛋白血症成人患者	Blood and bone marrow cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
62	IDARUBICIN	Acute myeloid leukaemia  Acute lymphoblastic leukaemia	Blood and bone marrow cancer	General Drugs	MIMS HK
63	IFOSFAMIDE	Germ cell testicular carcinoma	Testicular cancer	Speical Drugs	MIMS HK
64	IMATINIB	Accelerated phase Philadelphia chromosome positive chronic myelogenous leukaemia, Blast phase Philadelphia chromosome positive chronic myelogenous leukaemia  Chronic phase Philadelphia chromosome positive chronic myelogenous leukaemia  Philadelphia chromosome-positive acute lymphoblastic leukaemia  Myelodysplastic/myeloproliferative disease Dermatofibrosarcoma protuberans Gastrointestinal stromal tumour 胃腸道間質瘤 Dermatofibrosarcoma protuberans	Blood and bone marrow cancer  Gastrointestinal cancer  Skin cancer	Speical Drugs  Self-financed item With Safety Net (Samaritan Fund)  Special Drugs	MIMS HK  HA Website  MIMS HK
65	INOTUZUMAB OZOGAMICIN	As monotherapy for the treatment of transplant-eligible adult patients with relapsed or refractory CD22-positive B cell acute lymphoblastic leukaemia (ALL) that is either Philadelphia chromosome negative, or Philadelphia chromosome positive failing at least 1 prior TKI treatment 作為單一使用的藥物· 用於治療適合移植的復發或難治性 CD22 陽性 B 細胞急性淋巴細胞白血病的成年患者· 並為費城染色體陰性或費城染色體陽性而之前使用過至少一種酪氨酸激酶抑制劑(TKI)治療無效	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
66	IRINOTECAN	Metastatic adenocarcinoma of pancreas	Pancreatic cancer	General Drugs	MIMS HK
67	ISATUXIMAB AND POMALIDOMIDE	In combination with dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last therapy 與泊地塞米松聯合使用, 作為治療患有復發性或難治性的多發性骨髓瘤的成年患者, 而這些患者先前已接受過包括來那度胺及蛋白酶體抑制劑的至少兩種療法, 並在最後療程出現病情惡化	Bone marrow cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
68	IXAZOMIB	In combination with dexamethasone for the treatment of multiple myeloma in patients who have received at least one prior therapy 與地塞米松組合使用· 用於治療曾接受最少一次先前療程的多發性骨髓瘤患者	Bone marrow cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
69	LANREOTIDE	Carcinoid syndrome	Neuroendocrine cancer	Speical Drugs	MIMS HK
70	LENALIDOMIDE	Myelodysplastic syndrome  Multiple myeloma (MM) 多發性骨髓瘤  In combination with dexamethasone for the treatment of multiple myeloma in patients who have received at least one prior therapy 與地塞米松組合使用· 用於治療曾接受最少一次先前療程的多發性骨髓瘤患者  Multiple myeloma Mantle cell Lymphoma, Follicular Lymphoma, Marginal zone Lymphoma	Blood and bone marrow cancer  Bone marrow cancer	Self-financed item Without Safety Net  Self-financed item With Safety Net (Samaritan Fund)  Self-financed item With Safety Net (CCF Medical Assistance Programmes)	MIMS HK  HA Website  MIMS HK
71	LENVATINIB	Unresectable hepatocellular carcinoma (HCC) 無法以手術切除腫瘤的肝癌 Treatment of adult patients with progressive, locally advanced or metastatic, differentiated thyroid carcinoma (papillary/follicular/poorly differentiated/oncocytic carcinoma), refractory to radioactive iodine 進展性、局部晚期或轉移性、放射性碘難治性分化型甲狀腺癌成人患者的治療	Liver cancer  Thyroid cancer	Self-financed item With Safety Net (Samaritan Fund)  Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website  HA Website
72	LENVATINIB AND PEMBROLIZUMAB	Lenvatinib in combination with pembrolizumab, is indicated for the treatment of patients with advanced endometrial carcinoma (EC) that is mismatch repair proficient (pMMR), as determined by a validated test, or not microsatellite instability-high (MSI-H), who have disease progression following Lenvatinib in combination with pembrolizumab, is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC)	Endometrial cancer  Kidney cancer	Self-financed item Without Safety Net  Self-financed item Without Safety Net	MIMS HK  MIMS HK

73	LOMUSTINE	Lung cancer Hodgkin's Lymphoma Metastatic malignant melanoma	Lung cancer Lymphatic system cancer Skin cancer	General Drugs General Drugs General Drugs	MIMS HK MIMS HK MIMS HK
74	LORLATINIB	For the treatment of patients with ALK-positive metastatic NSCLC whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or alectinib or ceritinib or brigatinib as the first ALK inhibitor therapy for metastatic disease 用於治療患有間變性淋巴瘤激酶呈陽性，轉移性非小細胞肺癌，而且曾於接受以下的療程後仍出現病情惡化的成年患者： • 克唑替尼和至少另外一種間變性淋巴瘤激酶抑制劑作轉移性疾病的治療；或 • 阿來替尼或塞瑞替尼或布格替尼為第一種間變性淋巴瘤激酶抑制劑作轉移性疾病的治療  Untreated ALK-positive advanced non-small-cell lung cancer	Lung cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)  Self-financed item Without Safety Net	HA Website
75	MELPHALAN	Acute lymphoblastic leukaemia Trophoblastic neoplasm Burkitt's Lymphoma Choriocarcinoma	Blood and bone marrow cancer Gestational trophoblastic cancer Lymphatic system cancer Trophoblastic cancer	General Drugs General Drugs General Drugs General Drugs	MIMS HK MIMS HK MIMS HK MIMS HK
76	MERCAPTOPURINE	Acute lymphoblastic leukaemia	Blood and bone marrow cancer	General Drugs	MIMS HK
77	METHOTREXATE	Acute lymphoblastic leukaemia Trophoblastic neoplasm Burkitt's Lymphoma Choriocarcinoma	Blood and bone marrow cancer Gestational trophoblastic cancer Lymphatic system cancer Trophoblastic cancer	General Drugs General Drugs General Drugs General Drugs	MIMS HK MIMS HK MIMS HK MIMS HK
78	MIDOSTAURIN	Acute myeloid leukaemia (AML) 急性骨髓性白血病 Systemic mastocytosis (SM) 全身性肥大細胞增生症	Blood and bone marrow cancer Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund) Self-financed item Without Safety Net	 HA Website
79	MITOMYCIN	Superficial bladder tumours Head and neck cancer Pancreatic cancer	Bladder cancer Head and neck cancer Pancreatic cancer	General Drugs General Drugs General Drugs	MIMS HK MIMS HK MIMS HK
80	MITOXANTRONE	Blast crisis in chronic myeloid leukaemia, Acute myeloid leukaemia Non-Hodgkin's Lymphoma	Blood and bone marrow cancer Lymphatic system cancer	Spceial Drugs Spceial Drugs	MIMS HK MIMS HK
81	NILOTINIB	Dasatinib-resistant chronic myeloid leukaemia (CML) 對達沙替尼(Dasatinib) 具抗藥性的慢性骨髓性白血病  Imatinib-resistant chronic myeloid leukaemia (CML) 對伊馬替尼(Imatinib) 具抗藥性的慢性骨髓性白血病  Newly diagnosed chronic myeloid leukaemia (CML) in chronic phase 處於慢性期及新診斷的慢性骨髓性白血病	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
82	NIRAPARIB (TOSYLATE)	Fallopian tube cancer primary peritoneal cancer	Fallopian tube cancer Peritoneal cancer	Self-financed item Without Safety Net Self-financed item Without Safety Net	MIMS HK MIMS HK
83	NIRAPARIB (ZEJULA)	Ovarian cancer	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item Without Safety Net	HA Website
84	NIVOLUMAB	Metastatic urothelial carcinoma  In combination with fluoropyrimidine- and platinum-based combination chemotherapy for the 1st line treatment of adult patients with human epidermal growth factor receptor 2 negative (HER2-ve) advanced or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma whose tumours express PD-L1 with CPS $\geq$ 5 聯合氟嘧啶和含鉑組合化療作為第一線治療，用於 HER2 陰性之晚期或轉移性胃腺癌、胃食道交界處腺癌或食道腺癌的成年患者，而腫瘤須呈 PD-L1 陽性 (綜合陽性分數 $\geq$ 5) For the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after platinum based therapy 治療接受含鉑化療時或之後疾病惡化的復發或轉移性頭頸部鱗狀細胞癌(SCCHN)病人 Locally advanced squamous cell carcinoma of the head and neck  Metastatic squamous cell carcinoma of the head and neck  Hepatocellular carcinoma  EGFR-ve and ALK-ve metastatic non-small cell lung cancer (NSCLC) progressed on or following platinum-based chemotherapy 用於患有 EGFR 基因變異陰性及 ALK-陰性轉移性非小細胞肺癌(NSCLC) 並曾接受含鉑化療而病情惡化的患者	Bladder cancer Gastrointestinal cancer Head and neck cancer Head and neck cancer Head and neck cancer Liver cancer Lung cancer	Self-financed item Without Safety Net Self-financed item Without Safety Net Self-financed item With Safety Net (CCF Medical Assistance Programmes) Self-financed item With Safety Net (CCF Medical Assistance Programmes) Self-financed item With Safety Net (Samaritan Fund) Self-financed item Without Safety Net Self-financed item Without Safety Net Self-financed item With Safety Net (Samaritan Fund)	MIMS HK HA Website HA Website HA Website MIMS HK MIMS HK HA Website

		Refractory classical Hodgkin Lymphoma Unresectable or metastatic melanoma 不可切除或轉移性黑色素瘤	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
		Unresectable or metastatic melanoma 不可切除或轉移性黑色素瘤 For adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection 作為輔助性治療，用於腫瘤已擴散至淋巴結或其他部位，並已完全切除腫瘤的黑色素瘤患者	Skin cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
		Metastatic melanoma	Skin cancer	Self-financed item Without Safety Net	MIMS HK
85	NIVOLUMAB AND IPILIMUMAB	For the treatment of patients with intermediate or poor risk, previously untreated advanced renal cell carcinoma 作為中度或高風險的晚期腎細胞癌患者的初始治療一線治療	Kidney cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
		In combination with 2 cycles of platinum double chemotherapy for first-line treatment of adult patients with metastatic or recurrent squamous NSCLC with no EGFR or ALK genomic tumor aberrations 聯合兩個週期的鉑類雙藥化療，用於沒有表皮生長因子受體(EGFR)或間變性淋巴瘤激酶(ALK)基因突變的轉移性或復發鱗狀非小細胞肺癌的成年患者，作一線治療	Lung cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
86	OBINUTUZUMAB	In combination with Chlorambucil for treatment of previously untreated Chronic lymphocytic leukaemia (CLL) in adult patients with comorbidities making them unsuitable for full-dose Fludarabine or Bendamustine based therapy 適用於與苯丁酸氮芥(Chlorambucil)併用，治療先前未曾接受過治療，且具有合併症而不適合接受全劑量含氟達拉濱(Fludarabine)或苯達莫司汀(Bendamustine)治療的慢性淋巴細胞白血病患者	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund & CCF Medical Assistance Programmes)	HA Website
		Chronic lymphocytic leukaemia	Blood and bone marrow cancer	Self-financed item Without Safety Net	MIMS HK
		Follicular Lymphoma 濾泡性淋巴瘤	Lymphatic system cancer	Self-financed item With Safety Net (Samaritan Fund & CCF Medical Assistance Programmes)	HA Website
		Refractory follicular Lymphoma, Relapsed follicular Lymphoma	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
87	OCTREOTIDE	Severe secretory diarrhoea associated with vasoactive intestinal peptide-secreting tumour Diarrhoea associated with carcinoid tumour Flushing associated with carcinoid tumour Necrolytic migratory erythema associated with glucagonoma	Neuroendocrine cancer	General Drugs	MIMS HK
			Pancreatic cancer	General Drugs	MIMS HK
88	OLAPARIB	As maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade fallopian tube cancer who are in complete or partial response after first-line platinum based chemotherapy ( FIGO III-IV 期 ) 高分化晚期上輸卵管癌患者，有 BRCA 1/2 基因突變 ( 生殖細胞及 / 或體細胞突變 ) 而完成一線鉑類化療療程後有完全或部分緩解	Fallopian tube cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
		As maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian cancer who are in complete or partial response after first-line platinum based chemotherapy. ( FIGO III-IV 期 ) 高分化晚期上皮性卵巢癌患者，有 BRCA 1/2 基因突變 ( 生殖細胞及 / 或體細胞突變 ) 而完成一線鉑類化療療程後有完全或部分緩解的維持治療	Ovarian cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
		As maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade primary peritoneal cancer who are in complete or partial response after first-line platinum based chemotherapy ( FIGO III-IV 期 ) 高分化晚期上原發性腹膜癌成人患者，有 BRCA 1/2 基因突變 ( 生殖細胞及 / 或體細胞突變 ) 而完成一線鉑類化療療程後有完全或部分緩解的維持治療	Peritoneal cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
		Metastatic castration-resistant prostate cancer (mCRPC) 轉移性去勢療法無效前列腺癌	Prostate cancer	Self-financed item Without Safety Net	HA Website
89	PACLITAXEL	HER2-overexpressing advanced or metastatic breast cancer	Breast cancer	General Drugs	MIMS HK
		AIDS-related Kaposi's sarcoma	Endothelial cell cancer	General Drugs	MIMS HK
		Metastatic adenocarcinoma of pancreas	Pancreatic cancer	General Drugs	MIMS HK
90	PACLITAXEL (ALBUMIN)	HER2-overexpressing advanced or metastatic breast cancer	Breast cancer	Self-financed item Without Safety Net	MIMS HK
		AIDS-related Kaposi's sarcoma	Endothelial cell cancer	Self-financed item Without Safety Net	MIMS HK
		Metastatic adenocarcinoma of pancreas	Pancreatic cancer	Self-financed item Without Safety Net	MIMS HK
91	PAZOPANIB	Advanced soft tissue sarcoma	Bone or soft tissue cancer	Self-financed item With Safety Net (Samaritan Fund)	MIMS HK
92	PEGASPARAGINASE	Acute lymphoblastic leukaemia	Blood and bone marrow cancer	Speical Drugs	MIMS HK
93	PEMBROLIZUMAB	First-line treatment for metastatic non-small cell lung cancer (NSCLC) with high PD-L1 expression with no EGFR or ALK genomic tumor aberrations 用於PD-L1水平高，且沒有表皮生長因子受體(EGFR)或間變性淋巴瘤激酶(ALK)基因突變的轉移性非小細胞肺癌，作一線治療	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
		Metastatic urothelial carcinoma	Bladder cancer	Self-financed item Without Safety Net	MIMS HK

		Treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy 治療局部晚期或轉移性泌尿道上皮癌，用於在接受鉑類組合化療期間或之後出現病情惡化，或於十二個月內接受過鉑類組合化療作為術前或術後治療 Triple-negative breast cancer	Bladder cancer Breast cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes) Self-financed item Without Safety Net	HA Website HA Website
		PD-L1 expression in metastatic cervical cancer PD-L1 expression in recurrent cervical cancer Metastatic microsatellite instability-high colorectal cancer	Cervical cancer Colorectal cancer	Self-financed item Without Safety Net Self-financed item Without Safety Net	MIMS HK MIMS HK
		PD-L1 expression in metastatic gastroesophageal junction adenocarcinoma PD-L1 expression in recurrent locally advanced gastroesophageal junction adenocarcinoma PD-L1 expression in metastatic squamous cell carcinoma of the head and neck PD-L1 expression in unresectable recurrent squamous cell carcinoma of the head and neck Metastatic squamous cell carcinoma of the head and neck Recurrent squamous cell carcinoma of the head and neck	Esophagus cancer Head and neck cancer	Self-financed item Without Safety Net Self-financed item Without Safety Net	MIMS HK MIMS HK
		In combination with platinum and fluorouracil (FU) for the first-line treatment of patients with metastatic or with unresectable, recurrent head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 (CPS >=1) as determined by a validated test 與含鉑化療藥物及氟尿嘧啶合併使用作為第一線治療已經擴散，或復發並無法以手術切除的頭頸部鱗狀細胞癌，患者腫瘤“PD-L1”測試結果呈陽性(CPS >=1)	Head and neck cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
		First-line treatment for metastatic non-small cell lung cancer (NSCLC) with high PD-L1 expression with no EGFR or ALK genomic tumor aberrations 用於PD-L1水平高，且沒有表皮生長因子受體(EGFR)或間變性淋巴瘤激酶(ALK)基因突變的轉移性非小細胞肺癌，作一線治療	Lung cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
		In combination with carboplatin and paclitaxel for first-line treatment of adult patients with metastatic squamous NSCLC with PD-L1 expression (Tumor Proportion Score 1-49%) and no EGFR or ALK genomic tumor aberrations 聯合卡铂和紫杉醇類化療，用於沒有表皮生長因子受體(EGFR)或間變性淋巴瘤激酶(ALK)基因突變的轉移性鱗狀非小細胞肺癌的成年患者而其 PD-L1 水平腫瘤比例評分為 1-49%，作一線治療	Lung cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
		In combination with pemetrexed and platinum chemotherapy for first-line treatment of metastatic nonsquamous NSCLC with PD-L1 expression (Tumor Proportion Score 1-49%) with no EGFR or ALK genomic tumor aberrations 聯合培美曲塞及含鉑化療，用於沒有表皮生長因子受體(EGFR)或間變性淋巴瘤激酶(ALK)基因突變的轉移性非鱗狀非小細胞肺癌的患者，而其 PD-L1 水平腫瘤比例評分為 1-49%，作一線治療	Lung cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
		As monotherapy for the treatment of adult patients with relapsed or refractory classical Hodgkin Lymphoma (cHL) who have failed autologous stem cell transplant (ASCT) and Brentuximab Vedotin (BV), or who are transplant-ineligible and have failed BV 單一治療用於成人患者，治療復發或難治性典型何傑金氏淋巴瘤(cHL)，而患者已曾接受自身幹細胞移植(ASCT)及維布妥昔單抗(BV)治療但失敗，或 不合適自身幹細胞移植及曾接受維布妥昔單抗(BV)治療但失敗	Lymphatic system cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
		As monotherapy for the treatment of paediatric patients aged 3 years and older with relapsed or refractory cHL who have failed ASCT or following at least two prior therapies when ASCT is not a treatment option 單一治療用於三歲或以上的兒童患者，治療復發或難治性典型何傑金氏淋巴瘤(cHL)，而患者曾接受自體幹細胞移植(ASCT)治療但無效，或無法接受 自體幹細胞移植及曾接受自體幹細胞移植(ASCT)治療但無效	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
		Refractory classical Hodgkin Lymphoma, Relapsed classical Hodgkin Lymphoma, Primary mediastinal large B-cell Lymphoma Metastatic melanoma	Lymphatic system cancer Skin cancer	Self-financed item Without Safety Net Self-financed item Without Safety Net	MIMS HK MIMS HK
94	PEMETREXED	Malignant pleural mesothelioma	Lung cancer	Special Drugs	MIMS HK
95	PLERIXAFOR	Multiple myeloma (MM) 多發性骨髓瘤 Non-Hodgkin's Lymphoma (NHL) 非何傑金氏淋巴瘤	Bone marrow cancer Lymphatic system cancer	Self-financed item With Safety Net (Samaritan Fund) Self-financed item With Safety Net (Samaritan Fund)	HA Website HA Website
96	POLATUZUMAB VEDOTIN AND RITUXIMAB	Previously untreated diffuse large B-cell lymphoma (DLBCL)	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
97	POLATUZUMAB VEDOTIN, RITUXIMAB AND BENDAMUSTINE	For the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant 用於治療復發性/難治性瀰漫性大 B 細胞淋巴瘤 (DLBCL)，而不適合進行造血幹細胞移植的成人患者	Lymphatic system cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
98	POMALIDOMIDE	Multiple myeloma (MM) 多發性骨髓瘤	Bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
99	PONATINIB	Acute lymphoblastic leukaemia (ALL) 急性淋巴細胞白血病  Chronic myeloid leukaemia (CML) 慢性骨髓性白血病	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
100	PROCARBAZINE	Hodgkin's disease	Lymphatic system cancer	General Drugs	MIMS HK
101	REGORAFENIB	Unresectable, metastatic malignant gastrointestinal stromal tumours	Gastrointestinal cancer	Self-financed item Without Safety Net	MIMS HK



102	RITUXIMAB	Maintenance therapy for relapsed follicular Lymphoma (RFL) 復發濾泡性淋巴瘤的維持性治療  Previously-untreated and relapsed / refractory Chronic lymphocytic leukaemia (CLL) 從未治療及復發 / 難治慢性淋巴細胞白血病  CD20 positive diffuse large B-cell Lymphoma 瀰漫性大型 B 細胞非何杰金氏淋巴瘤  CD20 positive diffuse Burkitt Lymphoma 瀰漫性伯基特淋巴瘤  CD20 positive diffuse Burkitt leukaemia 瀰漫性伯基特白血病  Post-essential thrombocythemia myelofibrosis, Post-polythaemia vera myelofibrosis, Primary myelofibrosis, Polythaemia vera	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website MIMS HK
		Refractory follicular Lymphoma Relapsed follicular Lymphoma Chronic lymphocytic leukaemia	Blood and bone marrow cancer	Special Drugs	MIMS HK
		Refractory follicular Lymphoma Relapsed follicular Lymphoma CD20-positive diffuse large B cell Non-Hodgkin's Lymphoma CD20-positive non-progressing low-grade Non-Hodgkin's Lymphoma Advanced follicular Non-Hodgkin's Lymphoma	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
103	RUXOLITINIB	Chronic lymphocytic leukaemia	Blood and bone marrow cancer	Self-financed item Without Safety Net	MIMS HK
		CD20-positive diffuse large B cell Non-Hodgkin's Lymphoma Advanced follicular Non-Hodgkin's Lymphoma CD20-positive non-progressing low-grade Non-Hodgkin's Lymphoma	Lymphatic system cancer	Special Drugs	MIMS HK
104	SELUMETINIB	for the treatment of paediatric patients 2 years of age and older with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas	Brain cancer	Self-financed item Without Safety Net	LegCo Website
105	SORAFENIB	Hepatocellular carcinoma (HCC) 肝細胞癌	Liver cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
106	SUNITINIB	Gastrointestinal tumour 腸胃癌 Advanced Renal Cell Carcinoma (RCC)	Gastrointestinal cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
		Advanced Pancreatic Neuroendocrine Tumors (pNET)	Kidney cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	MIMS HK
			Pancreatic cancer	Self-financed item Without Safety Net	MIMS HK
107	TEMOZOLOMIDE	Glioblastoma multiforme, Refractory anaplastic astrocytoma, Anaplastic astrocytoma, Recurrent glioblastoma multiforme Recurrent high grade glioma 復發的惡性神經膠質瘤	Brain cancer Brain cancer	Special Drugs Self-financed item With Safety Net (Samaritan Fund)	MIMS HK HA Website
108	THALIDOMIDE	Multiple myeloma	Bone marrow cancer	General Drugs	MIMS HK
109	THIOGUANINE	Acute lymphoblastic leukaemia, Acute myeloid leukaemia, Chronic myeloid leukaemia	Blood and bone marrow cancer	General Drugs	MIMS HK
110	TOPOTECAN	Cervical cancer Small cell lung cancer	Cervical cancer Lung cancer	Self-financed item Without Safety Net Self-financed item Without Safety Net	MIMS HK MIMS HK
111	TRAMETINIB	For the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma 用於成年患者以治療 BRAF V600 突變呈陽性而不能切除的或轉移性黑色素瘤  For the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection 作為術後輔助治療，用於已完全切除腫瘤的 BRAF V600 突變 III 期黑色素瘤成人患者	Skin cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
112	TRASTUZUMAB DERUXTECAN	As monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens	Breast cancer	Self-financed item Without Safety Net	MIMS HK
113	TRETINOIN	Acute promyelocytic leukaemia	Blood and bone marrow cancer	General Drugs	MIMS HK
114	TRIFLURIDINE AND TIPIRACIL	For the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy	Gastrointestinal cancer	Self-financed item Without Safety Net	HA Website, MIMS HK
115	VEMURAFENIB	As monotherapy for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma 用於成年病人以治療 BRAF V600 突變呈陽性而不能切除的或轉移性黑色素瘤的單一療法	Skin cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website

116	VENETOCLAX	Newly diagnosed acute myeloid leukaemia (AML) 新確診的急性髓性白血病	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
		Chronic lymphocytic leukaemia, Small lymphocytic Lymphoma	Blood and bone marrow cancer	Self-financed item Without Safety Net	MIMS HK
117	VINBLASTINE	Advanced mycosis fungoides	Blood cancer	General Drugs	MIMS HK
		Kaposi's sarcoma	Endothelial cell cancer	General Drugs	MIMS HK
		Testicular cancer	Germ cell tumor	General Drugs	MIMS HK
		Langerhans cell histiocytosis	Histiocytes cancer	General Drugs	MIMS HK
		Hodgkin's disease, Lymphocytic Lymphoma	Lymphatic system cancer	General Drugs	MIMS HK
		Acute lymphoblastic leukaemia, Acute myeloid leukaemia	Blood and bone marrow cancer	General Drugs	MIMS HK
		Wilm's tumour	Kidney cancer	General Drugs	MIMS HK
		Small cell lung cancer	Lung cancer	General Drugs	MIMS HK
118	ZANUBRUTINIB	Hodgkin's disease, Non-Hodgkin's Lymphoma	Lymphatic system cancer	General Drugs	MIMS HK
		Waldenstrom's macroglobulinemia	Lymphatic system cancer	Self-financed item Without Safety Net	HA Website

**\*Drug Formulary Category refers to the Hospital Authority "Drug Formulary" categories**

**\*藥物名冊分類 是指醫院管理局《藥物名冊》分類**

General Drugs 通用藥物	These are drugs with well-established indications and cost-effectiveness which are available for general use as indicated by patients with relevant clinical conditions and provided at standard fees and charges in public hospitals and clinics. 經證實對病人有關臨床情況適用和有效，並可供一般使用的藥物。公立醫院和診所提供這類藥物時，會收取標準費用。
Special Drugs 專用藥物	These are drugs used under specific clinical conditions with specific specialist authorisation. Special drugs are provided at standard fees and charges in public hospitals and clinics when prescribed under specific clinical conditions. Patients who do not meet the specified clinical conditions but choose to use Special drugs are required to pay for the drugs. 在特定臨床應用下經專科醫生特別授權使用的藥物。如這類藥物是在特定的臨床應用下處方，公立醫院和診所會收取標準費用。如個別病人在特定臨床應用以外選擇使用專用藥物，便需自行支付藥物的費用。
Self-financed Items (SFIs) with Safety Net 獲安全網資助的自費購買藥物 (自費藥物)	These are drugs which are proven to be of significant clinical benefits but are very expensive for HA to provide as part of its standard services. These drugs are not covered by the standard fees and charges in public hospitals and clinics. Patients who require these drugs and can afford the costs have to purchase the drugs at their own expense. A safety net is provided through relevant funds to subsidize the drug expenses of patients who have financial difficulties. 經證實有顯著療效，但超出醫管局一般資助服務範圍所能提供的非常昂貴藥物。這些藥物不屬公立醫院和診所標準收費提供的項目。需要使用這些藥物而有能力負擔費用的病人須自費購買。然而，相關基金會為需要這些藥物而經濟上有困難的病人提供安全網。
SFIs without Safety Net 不獲安全網資助的自費藥物	These include drugs with preliminary medical evidence only, drugs with marginal benefits over available alternatives but at significant higher costs, and lifestyle drugs (e.g. anti-obesity drugs). These drugs are not provided as part of HA's standard services nor covered by the standard fees and charges in public hospitals and clinics. Patients who choose to use these drugs must purchase them at their own expense. 僅經初步醫療驗證的藥物、與其他替代藥物相比僅具邊緣效益，但成本明顯昂貴的藥物，以及生活方式藥物(例如減肥藥)。這些藥物並不會包括在標準收費範圍內，病人需自費購買。

(Source of information 資料來源： <https://www.ha.org.hk/hadf/en-us/Drug-Formulary-Management.html> )